Search Results for “cancer” – Page 144 – media

Faron shares almost crashed 90% on Traumakine failure

Finland pharmaceuticals company Faron (AIM: FARN) has crashed almost 90% of its shares, as the company announced the Phase III INTEREST trial of traumakine failed to meet its efficacy endpoint.
- Source: Ddu
- 676
- May 11, 2018
COPD Researches
Lodo Therapeutics Corporation Forms Multi-Target Strategic Collaboration with Genentech

Lodo Therapeutics Corporation, a drug discovery and development company focused on identifying and producing unique, bioactive natural products directly from the microbial DNA sequence information contained in soil, today announced that it has formed a strategic drug discovery collaboration with Genentech, a member of the Roche Group.
- Source: pharmalive
- 644
- May 11, 2018
Genentech Roche
World’s first Train Hospital helping rural Indian population

The Lifeline Express was introduced to meet two gaps: giving medical treatment in the remotest villages and providing lower-income people with free treatment. The train runs all over India, reaching the remotest places and halting in one place for a month before proceeding.
- Source: Ddu
- 634
- May 9, 2018
healthcare India Researches
First-line use of Roche’s Tecentriq given priority review

US regulators are undertaking a priority review of Roche unit Genentech’s PD-L1 inhibitor Tecentriq, in combination with Avastin and standard chemotherapy for some patients with lung cancer.
- Source: pharmatimes
- 623
- May 9, 2018
Chemotherapy lung cancer Roche Tecentriq
New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors

New collaboration to explore the potential clinical benefits of two novel and complementary immuno-oncology mechanisms
- Source: prnewswire
- 665
- May 8, 2018
multiple cancer TAK-659 Takeda
FDA Approves CAR T Therapy for Large B-Cell Lymphoma Developed at University of Pennsylvania

Nation’s first approved personalized cellular therapy now available for second indication
- Source: pennmedicine.org
- 525
- May 8, 2018
B-cell lymphoma FDA Kymriah
Flatiron Health, acquired By Roche, Signs Three-Year Deal with Bristol-Myers

Flatiron announced a three-year agreement with Bristol-Myers Squibb (BMS) a leading pharma company from the US. BMS is planning to use Flatiron’s expertise to expand real-world evidence to develop Bristol’s experimental cancer drugs.
- Source: drugdu
- 662
- May 4, 2018
BMS Company Insights Roche
Robust start to 2018 for Roche, as group sales grow by 6%

In the first quarter of 2018, Swiss pharmaceuticals and diagnostics player Roche group’s sales rose by 6% to CHF 13.6 billion. Sales in the pharma division increased by 7% CHF 10.7 billion mainly by strong growth in Ocrevus and Perjeta.
- Source: drugdu
- 816
- May 4, 2018
Company Insights Roche
Tisagenlecleucel Granted FDA Approval for Large B-Cell Lymphoma

Based on data from the phase II JULIET study, tisagenlecleucel (Kymriah) has received FDA approval for the treatment of adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma—after 2 or more lines of systemic therapy.
- Source: targetedonc
- 3,679
- May 3, 2018
FDA New Approvals tisagenlecleucel
Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens

T-Stealth™ Oncolytic Virus Platform Expected to Further Strengthen Immunotherapy Platform and Capabilities
- Source: janssen
- 574
- May 3, 2018
acquisition Janssen oncolytic immunotherapies

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.